Benralizumab, an anti-interleukin-5 receptor [alpha] monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
The Lancet (British edition), 2016-10, Vol.388 (10056), p.2128 [Peer Reviewed Journal]Copyright Elsevier Limited Oct 29, 2016 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)31322-8 ;CODEN: LANCAO
Full text available
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||